Will More Data Make the Difference for Merck?

Merck was dealt a blow toward the end of December after one of its cholesterol drugs, called Tredaptive, failed its outcomes study. It looks like the pharma stalwart won't seek approval from the Food and Drug Administration for this drug, but it hasn't given up on this market just yet. The company announced yesterday that the FDA will review its other cholesterol-fighter, which is a combination of the drugs ezetimibe and atorvastatin.

This therapeutic was already denied approval back in March -- but will additional data give Merck the green light this time around? What other drugs should Merck investors be watching in 2013?

Health care analyst Max Macaluso tackles these questions in the following video.

What's inside Supernova?
If you're an investor looking for big long term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2178016, ~/Articles/ArticleHandler.aspx, 4/17/2014 6:39:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement